Meeting
2018 ASCO Annual Meeting
Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors.
Authors
Lianna Jean Marks
Memorial Sloan Kettering Cancer Center, New York, NY
Lianna Jean Marks , Daniel Diolaiti , Prabhjot Singh Mundi , Ervin Gaviria , Allison Rainey , Filemon Dela Cruz , Andrea Califano , Andrew Kung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10552)
DOI
10.1200/JCO.2018.36.15_suppl.10552
Abstract #
10552
Poster Bd #
225
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth.
First Author: Sankar N. Maity
Poster
2020 ASCO Virtual Scientific Program
Preclinical evaluation of XPO1 inhibition in Wilms tumors.
First Author: Michael Vincent Ortiz
Poster
2015 ASCO Annual Meeting
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
First Author: Ulrik Niels Lassen
Poster
2020 ASCO Virtual Scientific Program
Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.
First Author: Eoghan Ruadh Malone